Introduction: The State of the Mission
As the 2026 grant cycle officially commences, METAvivor—a leading voice in the metastatic breast cancer (MBC) community—finds itself at a critical juncture. Under the leadership of President Kelly Shanahan, M.D., the organization is doubling down on its commitment to funding high-impact, patient-centric research while navigating the complex realities of clinical trial participation and community-led advocacy. This report outlines the current trajectory of the organization, the pressing needs within the research ecosystem, and the personal experiences that drive the leadership’s dedication to progress.
I. Main Facts: The 2026 Grant Cycle and Research Priorities
METAvivor has officially opened its call for research grant applications for the 2026 cycle. This initiative serves as the cornerstone of the organization’s efforts to bridge the gap in metastatic breast cancer survival rates.
Call for Innovation
The organization is inviting researchers globally to submit proposals that address the unique challenges of MBC. This comes on the heels of a record-breaking 2025 cycle, which saw the volume of Letters of Intent (LoIs) double compared to previous years. This surge in interest underscores both the growing awareness of the need for targeted MBC research and the critical role organizations like METAvivor play in filling funding gaps left by traditional institutional pipelines.
The Human Element in Peer Review
A defining feature of the METAvivor grant process is the integration of both scientific experts and patient advocates in the review process. By including those living with the disease in the evaluation of LoIs and full grant applications, METAvivor ensures that the research funded is not only scientifically rigorous but also clinically relevant to the patient experience. The organization is currently seeking volunteers—both researchers and patients—to assist in this vital vetting process.
II. Chronology: A Roadmap for Scientific Progress
The progress against metastatic breast cancer is not linear; it is a series of strategic steps involving bench science, clinical trials, and advocacy.
- Pre-2025: METAvivor establishes a robust framework for peer-reviewed grant distribution, prioritizing research that directly impacts metastatic outcomes.
- 2025: The organization experiences a 100% increase in LoIs, signaling a potential shift in research interest toward metastatic disease.
- Early 2026: Official opening of the 2026 grant cycle. Dr. Kelly Shanahan begins participation in a multi-site clinical trial at the Sarah Cannon Research Institute in Nashville, highlighting the ongoing search for effective therapies.
- March 2026: Launch of collaborative initiatives, including the spotlight on the trial led by Dr. Lior Braunstein at Memorial Sloan Kettering (MSK).
- Future Outlook: The potential expansion of clinical trials beyond the initial New York and New Jersey sites, contingent upon early data and federal funding allocations.
III. Supporting Data: The Clinical Landscape
Clinical trials remain the lifeblood of advancement for patients with limited options. A key area of focus for the upcoming year is the exploration of localized treatments for systemic disease.
The MSK Oligometastatic Study
A featured trial for this season is led by Dr. Lior Braunstein at Memorial Sloan Kettering. This study examines the efficacy of a multimodal approach for patients with "oligometastatic" (minimal metastases) HER2+ MBC. The trial investigates whether a combination of surgical removal of the primary breast tumor and targeted radiation to metastatic sites can significantly improve patient outcomes.
While the study is currently localized to MSK facilities in New York and New Jersey, the potential for expansion remains high. This trial represents a shift in thinking, moving away from a "one-size-fits-all" systemic approach to a more nuanced, individualized treatment plan that treats the primary tumor as a potential driver of further metastatic progression.
Federal Funding and the NIH/NCI Pipeline
The organization is closely monitoring federal budget discussions. There is a proposed increase in funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI). If realized, this influx of capital would provide a much-needed boost to the broader oncology research landscape, potentially accelerating the speed at which laboratory discoveries are translated into human clinical trials.
IV. Official Perspectives: The Personal Cost of Progress
Dr. Kelly Shanahan’s leadership is defined by a unique perspective: she is both the President of METAvivor and a patient actively navigating the rigors of a clinical trial.
The "Logistics of Survival"
Writing from Nashville, Dr. Shanahan provides a candid look at the "financial and time toxicity" associated with specialized cancer care. For many patients, the most promising clinical trials are not located in their home states. This necessitates long-distance travel, creating immense emotional and financial strain. Dr. Shanahan’s own experience—commuting from California to Tennessee—serves as a poignant reminder of the barriers that still exist for patients seeking the latest medical advancements.
The Culture of Care
Despite the hardships of travel and the physical demands of treatment, Dr. Shanahan emphasizes the importance of community. Her interactions with staff at the Sarah Cannon Research Institute underscore the vital role of "Southern hospitality" and patient-centered environments in improving the quality of life for those undergoing treatment. Her commitment to exploring the cultural offerings of her trial sites, such as the Museum of African American Music and the Country Music Hall of Fame, highlights the importance of maintaining a sense of humanity and connection while in the "clinical trenches."
V. Implications: Community Engagement and Future Action
The success of METAvivor is inherently tied to its grassroots network of supporters, fundraisers, and volunteers.
Mobilizing for 2026
The organization is calling on its supporters to take a proactive role in the upcoming year:
- Fundraising: Supporters planning events for 2026 are urged to contact the organization early to coordinate calendars and leverage official fundraising platforms.
- Peer-to-Peer Support: METAvivor is actively seeking to expand its network of peer-to-peer support groups. These groups, led by trained volunteers, are essential for the emotional well-being of the MBC community.
- Committee Participation: Beyond fundraising, the organization is looking for individuals to join various committees to help guide its strategic initiatives.
The Path Forward
As spring approaches—a season often used as a metaphor for renewal and hope—the message from leadership is one of persistence. Whether one is a researcher, a donor, or a patient, the collective goal remains the same: to transform metastatic breast cancer from a terminal diagnosis into a manageable condition.
The work being done by Dr. Shanahan and the entire METAvivor team is a testament to the power of patient-led advocacy. By connecting the dots between clinical trial participants, academic researchers, and the donors who make it all possible, METAvivor is ensuring that the 2026 cycle is not just another year of business as usual, but a pivotal moment in the fight for more time and better lives.
Call to Action
For those interested in applying for a grant, volunteering for a committee, or leading a support group, the following resources are available:
- Grant Applications: Visit the Research Portal
- Reviewing Grants: Become a Reviewer
- Fundraising FAQs: Start a Fundraiser
- Support Groups: Lead or Join a Group
- General Inquiries: Email [email protected]
As Dr. Shanahan notes, "We cannot do the work we do without you." The resilience of the organization is matched only by the resilience of the patients it serves. As the organization moves through the 2026 cycle, the focus remains clear: accelerate research, provide support, and never stop fighting for the future of those living with metastatic breast cancer.
About the Author
